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INTRODUCTION
A substantial increase in local recurrence (LR) of the treated 
breast has become a significant issue with the increased use of 
breast conservation therapy (BCT). The incidence of LR in the 
remnant breast varies between 2-10% after 5 years [1,2], and 
LR continues to occur at about 1% per year following BCT [3]. 
Isolated regional lymph node recurrence (RR) is an uncommon 
pattern of recurrence, and occurs in only 1-3% of patients with 
early stage breast carcinoma after a mastectomy or BCT [1,4,5]. 
Because of its rarity, relatively few data are available regarding 
the effect of LR and RR on the development of distant metas-
tasis and survival in patients treated with BCT. 
Studies on the prognostic effect of time on LR and RR after 
BCT have reported conflicting results. While some studies have 
reported that prognosis of patients with late recurrence of more 
than 2-3 years is significantly better than that of patients with 
early recurrence within 2-3 years [6-8], another study found 
no significant effect of the interval from BCT to regional nod-
al recurrence on prognosis [9].
We hypothesized that the recurrence site (LR vs. RR) and 
time to recurrence (<3 vs. >3 years) might have prognostic 
relevance. In this study, the occurrence of LR and RR and time 
to LR and RR were considered together, and we tested for their 
ability to predict subsequent development of distant metasta-
sis and survival. 
METHODS
Study population
Between January 1993 and December 2006, 1,103 consecu-
tive patients with breast cancer were treated with BCT at       
Severance Hospital, Yonsei University College of Medicine, 
Seoul, Korea. We retrospectively reviewed the data. Among 
the patients, we excluded 82 (7.4%) with ductal carcinoma in 
situ, one (0.1%) with a T4 lesion, four (0.4%) with stage IV dis-
ease at diagnosis, two (0.2%) with LR/RR diagnosed less than 
3 months after initial surgery, and 32 (2.9%) with non-epithelial 
originating tumors (phyllodes, sarcoma, or lymphoma). Thir-
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ty-nine (3.5%) patients received neoadjuvant chemotherapy 
did not include to exclude the confounding effect of neoadju-
vant chemotherapy. We also excluded 33 patients (3.0%) who 
did not receive radiation therapy, and three patients (0.2%) 
who did not receive appropriate axillary dissection. Finally, 
907 patients comprised the study population.
BCT consisted of a wide resection of the primary tumor with 
an attempted margin of at least 1 cm and axillary staging fol-
lowed by definitive breast radiation with or without systemic 
therapy. Microscopic margins were outperformed as routine 
clinical practice, and the primary site was re-excised for patients 
with microscopically involved margins. Sentinel lymph node 
biopsy (SLNB) using radioisotope was started in early 2000 at 
our medical center, so SLNB was performed in 279 patients 
(30.7%). Among them, we did not perform an axillary dissec-
tion in 209 patients with a negative sentinel lymph node, and 
they were considered N0. 
Patients were treated with radiotherapy using tangential fields 
directed at the whole breast after conservative surgery. The whole 
breast dose was 50.4 Gy (range, 45-55.8 Gy) with 1.8-2 Gy per 
fraction. A tumor bed boost was performed with a 9-12 MeV 
electron beam. The median boost dose was 10 Gy (range, 10-
20 Gy). In cases with a close or positive resection margin, the 
total radiation dose including the boost dose was increased to 
65 Gy. As a rule, the irradiated volume involved the breast alone 
in patients with less than three positive lymph nodes. Cases 
with extracapsular lymph node extension or more than four 
positive lymph nodes were irradiated in the axilla or subclavic-
ular fossa. The internal mammary lymph node was not routinely 
irradiated if there was no evidence of tumor involvements by 
radiological tests.
Adjuvant chemotherapy was indicated for patients who were 
node positive and had high-risk node negative disease. Between 
1993 and 2004, patients with node negative disease received six 
cycles of cyclophosphamide, methotrexate, and 5-fluorouracil 
(CMF), whereas those with node positive disease received six 
cycles of 5-fluorouracil, doxorubicin, and cyclophosphamide 
(FAC). From 2005 until the end of the study, four cycles of 
doxorubicin plus cyclophosphamide (AC) were administered 
to those with node positive disease and four cycles of doxoru-
bicin plus cyclophosphamide followed by four cycles of taxane 
(AC→T) were administered to those with node positive disease. 
Among 798 patients with positive estrogen (ER) or progester-
one receptors (PR), only 539 patients (63.0%) received adjuvant 
endocrine therapy, because premenopausal women were ex-
cluded from endocrine therapy in the early period of this study.   
Tested variables
We retrospectively reviewed the patients’ clinicopathological 
data including age, tumor stage, lymph node status, histologi-
cal type, histological grade, ER/PR status, adjuvant systemic 
therapy, and follow-up data. LR was defined as histological ev-
idence of a new tumor occurring in the treated breast or over-
lying skin more than 3 months after the completion of defini-
tive surgery. The definition of RR was any biopsy-proven car-
cinoma found in the axilla or supraclavicular lymph nodes. 
Patient diagnosed with both LR and RR simultaneously were 
defined as RR. To evaluate the prognostic effect of LR and RR 
and time to recurrence, LR and RR were separated into four 
patterns: LR within 3 years (early LR), LR after 3 years (late LR), 
RR within 3 years (early RR), and RR after 3 years (late RR). 
Clinicopathological variables and patterns of LR and RR were 
tested for their ability to predict distant relapse free survival 
(DRFS) and overall survival (OS). All data were extracted from 
the Severance Hospital breast cancer registry which is a pro-
spectively maintained database and includes clinical informa-
tion, pathological information, treatment modalities, and out-
come details. 
Statistics
The primary end points of this analysis were DRFS and OS. 
Events determining DRFS were distant recurrence and death 
before recurrence. OS was death from any cause. Survival time 
was defined as the length of time from the date of surgery to 
the date of an event or the date last known to be alive. Survival 
rates were calculated by the Kaplan-Meier method, and the log-
rank test was used to compare the groups. Multivariate analyses 
were performed using Cox proportional hazard regression 
model to determine whether LR and RR patterns were inde-
pendent predictors of DRFS and OS. All reported p-values were 
two-sided, and a p-value <0.05 was considered significant.  
RESULTS
Patient characteristics
The clinicopathological characteristics of the study popula-
tion and LR and RR patterns are summarized in Table 1. At the 
time of initial diagnosis, 96 patients (10.6%) were under the age 
of 35, and 272 patients (30.0%) had T2 lesions. At the time of 
initial surgery, 254 patients (28.0%) had a positive axillary lymph 
node. Almost 90% of patients had invasive ductal carcinoma 
(808 of 907, 89.9%). Information on histological grade, ER and 
PR status, and adjuvant chemotherapy was available in 732, 846, 
847, and 903 patients, respectively. Approximately two-thirds 
of patients received adjuvant systemic chemotherapy and en-
docrine therapy. No significant differences were observed in 
the clinicopathological characteristics between LR and RR.
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(1.3%) developed RR as the first event, with a median follow-up 
time of 53 months (range, 4-179 months). None of the patients 
showed histological or radiological signs of distant metastasis 
at the time of LR and RR diagnosis (Table 1). The distribution 
of early LR, late LR, early RR, and late RR was 12 (1.3%), 16 
(1.8%), 5 (0.6%), and 7 (0.8%), respectively. Recurrent sites 
Table 1. Clinicopathologic, treatment characteristics, and patterns of local/regional recurrence
Characteristics
No locoregional recurrence, 
No. (%)
Local recurrence,  
No. (%)
Regional recurrence,  
No. (%)
p-value
Age (yr) 0.002
   ≤35 (n=96)   84 (87.5)   9 (9.4)    3 (3.1)
   >35 (n=811) 783 (96.5) 19 (2.3)    9 (1.1)
Tumor stage 0.580
   T1 (n=635) 606 (95.4) 19 (3.0)  10 (1.6)
   T2 (n=272) 261 (95.9)   9 (3.3)    2 (0.7)
Lymph node metastasis 0.242
   Negative (n=653) 621 (95.1) 24 (3.7)    8 (1.2)
   Positive (n=254) 246 (96.9)   4 (1.6)    4 (1.6)
Histologic type 0.064
   Ductal (n=808) 774 (95.8) 26 (3.2)    8 (1.0)
   Lobular (n=15)   14 (93.3)   1 (6.7) 0 (0)
   Others (n=84)   79 (94.0)   1 (1.2)    4 (4.8)
Histologic grade (n=732)*  0.441
   I (n=212) 203 (96.2)   5 (2.4)    3 (1.4)
   II/III (n=520) 501 (96.2) 17 (3.3)    3 (0.6)
ER status (n=846)* 0.204
   ER(-) (n=305) 289 (94.7) 13 (4.3)    3 (1.0)
   ER(+) (n=541) 521 (96.3) 12 (2.2)    8 (1.5)
PR status (n=847)* 0.390
   PR(-) (n=367) 349 (95.1) 11 (3.0)    7 (1.9)
   PR(+) (n=480) 462 (96.3) 14 (2.9)    4 (0.8)
Adjuvant chemotherapy (n=903)* 0.003
   Not done (n=306) 282 (92.2) 17 (5.6)    7 (2.3)
   Done (n=597) 581 (97.3) 11 (1.8)    5 (0.8)
Endocrine therapy (n=907) 0.011
   Not done (n=367) 343 (93.5) 19 (5.2)    5 (1.4)
   Done (n=540) 524 (97.0)   9 (1.7)    7 (1.3)
ER=estrogen receptor; PR=progesterone receptor.
*Histologic grade, ER and PR status, and adjuvant chemotherapy did not know whole data. The numbers in parentheses are data that can be known as the chart 
review.
Figure 1. Kaplan-Meier 5-year distant relapse free survival (A) and overall survival (B) estimate according to the patterns of local recurrence and regional 
recurrence. Early local recurrence (LR), local recurrence within 3 years; Late LR, local regional after 3 years; Early regional recurrence (RR), regional   
recurrence within 3 years; Late RR, regional recurrence after 3 years.
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were an ipsilateral breast (n=28, 70.0%), axillary lymph node 
(n=2, 5.0%), supraclavicular lymph node (n=9, 22.5%), and 
internal mammary lymph node (n=1, 2.5%). 
Among 653 patients with axillary node-negative disease, 209 
patients (32.0%) performed only SLNB and the rest 444 patients 
(68.0%) underwent axillary node dissection. Early LR, late LR, 
early RR, and late RR occurred in 1, 1, 0, and 1 patient among 
those who performed only SLNB, respectively, and 9, 13, 2, and 
4 patients among those who underwent ALND, respectively. 
Among patients with node-negative disease, SLNB alone did 
not lead to inferior locoregional control than ALND. 
At the time of the LR and RR diagnosis, 30 patients (75%) 
underwent surgical treatment including simple mastectomy 
with or without axillary dissection, or axillary dissection alone. 
Twelve patients (30%) were treated with additional radiother-
apy to regional lymph node. Chemotherapy was administered 
to 22 patients (55%), and 16 patients (40%) received endocrine 
therapy. Two patients (5%) received herceptin. 
Effect of LR and RR on DRFS and OS
Of the 40 patients who underwent LR and RR, 13 (32.5%) 
experienced subsequent distant recurrence. The distribution 
of early LR, late LR, early RR, and late RR was four (5.0%), three 
(3.8%), four (5.0%), and two (2.5%). The distance metastatic 
sites were bone (n=5), lung (n=7), liver (n=4), central nervous 
system (n=4), and other visceral organ (n=3). Eleven patients 
(27.5%) died after detection of LR and RR. Of 867 patients who 
did not undergo LR and RR, 67 (7.7%) experienced distance 
recurrence. Distance metastasis sites were bone (n=38), lung 
(n=37), liver (n=18), central nervous system (n=7), and other 
visceral organ (n=7). Fifty-seven patients (6.7%) died during 
the following-up period. The following factors were analyzed 
for their ability to predict DRFS and OS: age, T stage, lymph 
node status, histological type, histological grade, ER/PR status, 
adjuvant chemotherapy, endocrine therapy, and LR and RR 
patterns.
In a univariate analysis, younger age (≤35 years) at diagno-
sis (p=0.003), larger tumor size of more than 2 cm (p=0.008), 
positive lymph node (p<0.001), and early LR and early RR 
development (p<0.001) had a significant effect on DRFS. Pos-
itive lymph node status (p=0.005) and early LR and early RR 
development (p<0.001) had a significant effect on poor sur-
vival (Table 2, Figure 1). The 5-year DRFS for patients present-
ing with early LR and early RR was 65.6% and 0%, respectively. 
The 5-year OS of early LR and early RR was 66.8% and 30.0%, 
respectively. The 5-year DRFS and OS of late LR and late RR 
were similar compared with patients who never experienced 
LR and RR (Table 2). 
In multivariate analysis, younger age (≤35 years) (hazard 
ratio [HR], 1.79; 95% confidence interval [CI], 1.01-3.15; p= 
0.043), positive lymph node (HR, 2.34; 95% CI, 1.47-3.71; p< 
0.001), early LR (HR, 4.76; 95% CI, 1.69-13.34; p=0.003), and 
early RR (HR, 18.16; 95% CI, 6.34-52.00; p<0.001) were sig-
nificantly related with lower DRFS, whereas tumor size (HR, 
1.58; 95% CI, 1.00-2.51; p=0.05) had marginal significance. 
In terms of OS, a positive lymph node (HR, 2.10; 95% CI, 1.28-
3.45; p=0.003), early LR (HR, 5.24; 95% CI, 1.86-14.74; p= 
0.002), and early RR (HR, 18.80; 95% CI, 6.24-55.05; p<0.001) 
were significantly related to lower OS. No apparent difference 
Table 2. Univariate analysis for predicting 5 year distant relapse free sur-
vival and overall survival
Characteristics
5-yr  
DRFS (%)
p-value
5-yr  
OS (%)
p-value
Age (yr)
   ≤35 81.9 0.003 87.3 0.140
   >35 91.1 92.3
Tumor stage
   T1 92.1 0.008 92.3 0.536
   T2 86.0 90.6
Lymph node metastasis
   Negative 92.9 <0.001 93.8 0.005
   Positive 83.5 86.9
Histologic type
   Ductal 89.8 0.555 91.6 0.998
   Lobular 100 100
   Others 91.4 91.9
Histologic grade (n=732)*
   I 93.0 0.095 93.1 0.312
   II/III 88.2 90.0
ER status (n=846)*
   Negative 90.8 0.873 92.4 0.940
   Positive 90.0 91.8
PR status (n=847)*
   Negative 90.6 0.511 91.9 0.648
   Positive 90.1 92.1
Adjuvant chemotherapy (n=903)*
   Not done 89.5 0.934 91.2 0.385
   Done 90.3 91.9
Adjuvant endocrine therapy
   Not done 89.6 0.895 90.4 0.301
   Done 90.4 92.8
Patterns of LR/RR
   No LR/RR 90.9 <0.001 92.4 <0.001
   Early LR 65.6 66.8
   Late LR 93.8 100
   Early RR 0 30.0
   Late RR 85.7 100
DRFS=distant relapse free survival; OS=overall survival; ER=estrogen recep-
tor; PR=progesterone receptor; Early LR=local recurrence within 3 years; Late 
LR=local regional after 3 years; Early RR=regional recurrence within 3 years; 
Late RR=regional recurrence after 3 years.
*Histologic grade, ER and PR status, and adjuvant chemotherapy did not 
know whole data. The numbers in parentheses are data that can be known 
as the chart review.LocalandRegionalRecurrenceinBCT 195
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in DRFS and OS was found between patients who experienced 
late LR and RR and those who did not (Table 3).
DISCUSSION
The magnitude of problem of LR is substantial as many 
women choose BCT for initial management. RR is a relatively 
uncommon event, and few data are available regarding the   
association among RR, DRFS, and OS. However, as the num-
ber of long term survivors has increased, analysis of treatment 
outcomes has revealed that the LR and RR problem has a poten-
tial impact on DRFS and OS [10,11]. Evaluation of the prog-
nostic effect of LR and RR on the development of DR and sur-
vival following BCT may help to determine the treatment mo-
dality.
Several studies have focused on LR and RR as the first event 
after BCT and reported that LR and RR are significant predic-
tors of subsequent distant metastases and survival [4,12-16]. 
Additionally, it seems that the prognosis after RR is much worse 
than that after LR. According to an analysis of five trials con-
ducted by the National Surgical Adjuvant Breast and Bowel 
Project, the risks of distant disease and death were greater after 
RR than LR in each trial [17]. However, whether time to recur-
rence is a marker for distant metastasis remains controversial. 
Several studies have identified the time to LR and RR from 
initial surgery as an additional important prognostic factor for 
DRFS and OS [5,12-14,17-20], whereas another study report-
ed that the time to regional nodal recurrence did not have a 
significant effect on prognosis [9].
We separated LR and RR into four patterns-(early LR, late 
LR, early RR, and late RR) to evaluate the prognostic relevance 
of site of recurrence (LR vs. RR) and time to LR and RR (early 
vs. late) after BCT. The data presented here confirm that pa- 
tients who experience early LR and early RR within the first few 
years following their original diagnosis have a poor prognosis. 
LR and RR within 3 years was a strong predictor of develop-
ing distant recurrence and death. Early RR showed the worst 
prognostic patterns and the outcomes in these patients at 5 
years showed a DRFS of 0% and an OS of 30%, followed by an 
early LR. Although a trend was seen for higher rates of distant 
metastases in patients with late RR, it was not statistically sig-
nificant (HR, 2.89; 95% CI, 0.70-11.86; p=0.141). These find-
ings suggest that time to LR and RR is a more important prog-
nostic factor for distant metastases and survival than site of 
recurrence. We assumed that more rapidly recurring tumors 
have higher biological aggressiveness, and that patients who 
sustain early LR and early RR tend to display worse clinical 
behavior and a relatively unfavorable prognosis. 
Interestingly, the prognosis of patients who experienced late 
LR was not that different from that of patients who never ex-
perienced recurrence. A possible explanation for this finding 
is that a significant portion of patients who experience late LR 
following BCT develop new primary tumors as opposed to true 
LR [21]. True recurrence and a new primary tumor may have 
a different natural history, different biological behavior and a 
different prognosis. Theoretically, true recurrent tumors may-
be more radio-resistant and more drug-insensitive than a new 
primary tumor [17,21]. 
Prevention and prediction of LR and RR at the time of initial 
diagnosis of primary tumor might be an important issue if LR 
and RR, as the first event after BCT, influences DRFS and OS. 
Patients at high risk for LR and RR can benefit from initial   
aggressive surgery [22], but, no robust marker predicts the risk 
of locoregional failure, which would be helpful when selecting 
an ideal initial therapy [23]. A major effort is underway to pre-
dict LR and RR using molecular markers in genome-wide asso-
ciation studies. 
In the absence of data from prospective randomized trials, we 
suggest that the decision should be tailored to the risk of the 
individual patient based on the knowledge of a demonstrated 
Table 3. Hazard ratios and 95% confidence intervals by multivariate Cox model
Variables
DRFS OS
HR 95% CI p-value HR 95% CI p-value
Age (>35 vs. ≤35 yr)   1.79 1.01-3.15 0.043   1.29 0.66-2.52 0.437
Tumor stage (T1 vs. T2)   1.58 1.00-2.51 0.050   1.09 0.65-1.82 0.724
Node metastasis (negative vs. positive)   2.34 1.47-3.71 <0.001   2.10 1.28-3.45 0.003
Without LR/RR Ref. Ref.
   Early LR   4.76 1.69-13.34 0.003   5.24 1.86-14.74 0.002
   Late LR     1.319 0.40-4.35 0.650   0.97 0.22-4.19 0.977
   Early RR 18.16 6.34-52.00 <0.001 18.80 6.42-55.05 <0.001
   Late RR   2.89 0.70-11.86 0.141   1.43 0.19-10.39 0.722
DRFS=distance relapse free survival; OS=overall survival; HR=hazard ratio; CI=confidence interval; LR=local recurrence; RR=regional recurrence; Early 
LR=local recurrence within 3 years; Late LR=local regional after 3 years; Early RR=regional recurrence within 3 years; Late RR=regional recurrence after 3 years; 
Ref.=reference.196  JongSeokLee,etal.
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benefit of adjuvant systemic therapy in patients with primary 
cancer. Our data suggests that patients with early LR and early 
RR need to be considered as a clinically distinct group com-
pared with those who develop late LR and late RR. The high 
incidence of distant metastasis and death in patients who ex-
perienced early LR and early RR justifies considering more 
aggressive systemic therapy at the time of the LR and RR diag-
noses. Age, tumor size, and axillary lymph node status were 
also significantly related to distant recurrence and all should 
be considered for further adjuvant therapy.
We noted that patients who experienced late RR had a greater 
than 2.89 fold relative risk of developing distant metastasis with-
out statistical significance. Because the limited power of this 
study with a small number of patients was a possible cause for 
the failure to demonstrate a difference, our data could not pro-
vide definitive answers regarding the role of systemic treatment 
for patients with late RR. It seems reasonable to select systemic 
treatment strategies on an individual basis for patients who 
experience late LR and late RR. 
We included patients who had received appropriate radia-
tion, and standard axillary surgery and excluded patients who 
were administered inappropriate locoregional treatment. How-
ever, similar to other studies, an important limitation of this 
retrospective study was the small number of patients, as is appar-
ent from the broadness of the confidence intervals. Interpreta-
tion of the results is also hampered by the heterogeneity of the 
study population because of the long study duration and differ-
ent adjuvant systemic therapies used after initial surgery. Add- 
itionally, treatment strategies at the time of LR and RR were 
highly individualized given the lack of prospective data to make 
decisions regarding patients with LR and RR. 
Early LR and early RR within 3 years following BCT was a 
strong independent predictor of DRFS and OS, whereas sur-
vival of patients with late LR and late RR was not significantly 
different from those who never experienced LR and RR. Other 
prognostic factors (age, tumor size, positive axillary lymph node) 
were also important predictors of DRFS and OS. Aggressive 
systemic treatment should be considered for patients who ex-
perience early LR and early RR, whereas systemic treatment 
for patients with late LR and late RR could be determined on 
an individual basis. A multi-institutional study is necessary to 
establish a standard treatment protocol for patients who suffer 
from LR and RR following BCT. It may be possible in the future 
to tailor initial surgery for a primary tumor using biological 
marker that estimates the risk of local and regional failure.
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